Probability of CMV infection, mortality, and GVHD
| Variable . | aHR . | 95% CI . | P . |
|---|---|---|---|
| CMV (any viremia) | |||
| Vancomycin* | 1.225 | 0.626-2.397 | .55 |
| Cefepime* | 0.799 | 0.425-1.501 | .48 |
| Anaerobic antibiotics* | 1.427 | 0.929-2.192 | .10 |
| Mismatch/unrelated donor | 1.356 | 0.861-2.135 | .19 |
| CMV seronegative donor | 1.015 | 0.682-1.510 | .94 |
| GVHD 3-4 | 0.759 | 0.360-1.603 | .47 |
| Lymphoid malignancy | 1.276 | 0.836-1.946 | .26 |
| Clinically significant CMV infection | |||
| Vancomycin* | 0.961 | 0.422-2.193 | .93 |
| Cefepime* | 0.936 | 0.433-2.026 | .87 |
| Anaerobic antibiotics* | 1.937 | 1.176-3.193 | .01 |
| Mismatch/unrelated donor | 2.698 | 1.478-4.924 | .001 |
| CMV seronegative donor | 1.309 | 0.824-2.079 | .25 |
| GVHD 3-4 | 0.743 | 0.328-1.681 | .47 |
| Lymphoid malignancy | 2.184 | 1.339-3.560 | .002 |
| All-cause mortality | |||
| Vancomycin* | 0.94 | 0.32-2.78 | .91 |
| Cefepime* | 1.53 | 0.58-4.08 | .39 |
| Anaerobic antibiotics* | 3.11 | 1.60-6.04 | .0008 |
| Age | 1.02 | 0.99-1.05 | .06 |
| Mismatch/unrelated donor | 1.29 | 0.56-2.97 | .55 |
| Comorbidity score ≥2 | 0.84 | 0.33-2.15 | .71 |
| GVHD 3-4 | 1.92 | 0.81-4.56 | .14 |
| Acute leukemia† | 0.92 | 0.49-1.74 | .80 |
| cs-CMVi | 1.21 | 0.64-2.28 | .55 |
| Bacteremia as indication for antibiotics‡ | 0.83 | 0.33-2.08 | .69 |
| Nonrelapse mortality | |||
| Vancomycin* | 1.28 | 0.27-6.07 | .75 |
| Cefepime* | 2.65 | 0.68-10.4 | .16 |
| Anaerobic antibiotics* | 4.23 | 1.81-9.86 | .0008 |
| Age | 1.03 | 1.00-1.01 | .051 |
| Mismatch/unrelated donor | 1.26 | 0.42-3.78 | .68 |
| Comorbidity score | 0.41 | 0.15-1.10 | .08 |
| GVHD 3-4 | 1.79 | 0.66-4.87 | .26 |
| Acute leukemia† | 1.37 | 0.64-2.95 | .42 |
| cs-CMVi | 1.31 | 0.58-2.98 | .52 |
| Bacteremia as indication for antibiotics‡ | 0.93 | 0.33-2.62 | .89 |
| GVHD 3-4 | aOR | 95% CI | P |
| Vancomycin* | 8.91 | 0.73-109 | .09 |
| Cefepime* | 0.49 | 0.10-2.44 | .38 |
| Anaerobic antibiotics* | 5.46 | 1.24-24.0 | .02 |
| Mismatch/unrelated donor | 0.55 | 0.11-2.64 | .46 |
| Age | 0.99 | 0.95-1.04 | .83 |
| Graft source (PBSC) | 0.36 | 0.06-2.27 | .27 |
| Variable . | aHR . | 95% CI . | P . |
|---|---|---|---|
| CMV (any viremia) | |||
| Vancomycin* | 1.225 | 0.626-2.397 | .55 |
| Cefepime* | 0.799 | 0.425-1.501 | .48 |
| Anaerobic antibiotics* | 1.427 | 0.929-2.192 | .10 |
| Mismatch/unrelated donor | 1.356 | 0.861-2.135 | .19 |
| CMV seronegative donor | 1.015 | 0.682-1.510 | .94 |
| GVHD 3-4 | 0.759 | 0.360-1.603 | .47 |
| Lymphoid malignancy | 1.276 | 0.836-1.946 | .26 |
| Clinically significant CMV infection | |||
| Vancomycin* | 0.961 | 0.422-2.193 | .93 |
| Cefepime* | 0.936 | 0.433-2.026 | .87 |
| Anaerobic antibiotics* | 1.937 | 1.176-3.193 | .01 |
| Mismatch/unrelated donor | 2.698 | 1.478-4.924 | .001 |
| CMV seronegative donor | 1.309 | 0.824-2.079 | .25 |
| GVHD 3-4 | 0.743 | 0.328-1.681 | .47 |
| Lymphoid malignancy | 2.184 | 1.339-3.560 | .002 |
| All-cause mortality | |||
| Vancomycin* | 0.94 | 0.32-2.78 | .91 |
| Cefepime* | 1.53 | 0.58-4.08 | .39 |
| Anaerobic antibiotics* | 3.11 | 1.60-6.04 | .0008 |
| Age | 1.02 | 0.99-1.05 | .06 |
| Mismatch/unrelated donor | 1.29 | 0.56-2.97 | .55 |
| Comorbidity score ≥2 | 0.84 | 0.33-2.15 | .71 |
| GVHD 3-4 | 1.92 | 0.81-4.56 | .14 |
| Acute leukemia† | 0.92 | 0.49-1.74 | .80 |
| cs-CMVi | 1.21 | 0.64-2.28 | .55 |
| Bacteremia as indication for antibiotics‡ | 0.83 | 0.33-2.08 | .69 |
| Nonrelapse mortality | |||
| Vancomycin* | 1.28 | 0.27-6.07 | .75 |
| Cefepime* | 2.65 | 0.68-10.4 | .16 |
| Anaerobic antibiotics* | 4.23 | 1.81-9.86 | .0008 |
| Age | 1.03 | 1.00-1.01 | .051 |
| Mismatch/unrelated donor | 1.26 | 0.42-3.78 | .68 |
| Comorbidity score | 0.41 | 0.15-1.10 | .08 |
| GVHD 3-4 | 1.79 | 0.66-4.87 | .26 |
| Acute leukemia† | 1.37 | 0.64-2.95 | .42 |
| cs-CMVi | 1.31 | 0.58-2.98 | .52 |
| Bacteremia as indication for antibiotics‡ | 0.93 | 0.33-2.62 | .89 |
| GVHD 3-4 | aOR | 95% CI | P |
| Vancomycin* | 8.91 | 0.73-109 | .09 |
| Cefepime* | 0.49 | 0.10-2.44 | .38 |
| Anaerobic antibiotics* | 5.46 | 1.24-24.0 | .02 |
| Mismatch/unrelated donor | 0.55 | 0.11-2.64 | .46 |
| Age | 0.99 | 0.95-1.04 | .83 |
| Graft source (PBSC) | 0.36 | 0.06-2.27 | .27 |
Cox proportional hazards regression model was used for CMV and mortality. Logistic regression analysis was used to examine the risk factors for development of GVHD.
aHR, adjusted hazard ratio; aOR, adjusted odds ratio; CI, confidence interval; PBCS, peripheral blood stem cell.
Compared with reference (ie, no corresponding antibiotic).
Includes acute myeloid leukemia, acute lymphoid leukemia, and acute leukemia of ambiguous lineage.
Compared with reference (ie, antibiotics for prophylaxis, culture negative fever, and other).